StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$457.93−4.39 (-0.95%)

Close on Nov 17, 2026Market cap $247.57BP/E 26.5Yield 2.11%

Amgen cash

Cash and short-term investments held at the end of each period.

Amgen's cash was $13.19B at Sep 30, 2026. For fiscal 2025 it was $9.13B, down 23.8% from the year before. Over ten years it grew 8.2% a year on average. The highest annual figure on record is $41.68B in fiscal 2017.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$9.13B-23.8%
FY2024Dec 31, 2024$11.97B+9.4%
FY2023Dec 31, 2023$10.94B+17.6%
FY2022Dec 31, 2022$9.31B+15.8%
FY2021Dec 31, 2021$8.04B-24.5%
FY2020Dec 31, 2020$10.65B+19.5%
FY2019Dec 31, 2019$8.91B-69.6%
FY2018Dec 31, 2018$29.30B-29.7%
FY2017Dec 31, 2017$41.68B+1186.0%
FY2016Dec 31, 2016$3.24B-21.8%
FY2015Dec 31, 2015$4.14B+11.1%
FY2014Dec 31, 2014$3.73B-1.9%
FY2013Dec 31, 2013$3.81B+16.8%
FY2012Dec 31, 2012$3.26B-53.1%
FY2011Dec 31, 2011$6.95B+111.3%
FY2010Dec 31, 2010$3.29B+14.0%
FY2009Dec 31, 2009$2.88B+62.6%
FY2008Dec 31, 2008$1.77B-12.4%
FY2007Dec 31, 2007$2.02B+57.8%
FY2006Dec 31, 2006$1.28B–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$13.19B+39.7%
Q2 FY2026Jun 30, 2026$13.99B+74.3%
Q1 FY2026Mar 31, 2026$12.04B+36.6%
Q4 FY2025Dec 31, 2025$9.13B-23.8%
Q3 FY2025Sep 30, 2025$9.45B+4.8%
Q2 FY2025Jun 30, 2025$8.03B-13.7%
Q1 FY2025Mar 31, 2025$8.81B-9.3%
Q4 FY2024Dec 31, 2024$11.97B+9.4%
Q3 FY2024Sep 30, 2024$9.01B-74.1%
Q2 FY2024Jun 30, 2024$9.30B-72.8%
Q1 FY2024Mar 31, 2024$9.71B-69.2%
Q4 FY2023Dec 31, 2023$10.94B+17.6%
Q3 FY2023Sep 30, 2023$34.74B+202.7%
Q2 FY2023Jun 30, 2023$34.25B+376.8%
Q1 FY2023Mar 31, 2023$31.56B+382.3%
Q4 FY2022Dec 31, 2022$9.31B+15.8%
Q3 FY2022Sep 30, 2022$11.48B-11.2%
Q2 FY2022Jun 30, 2022$7.18B-32.0%
Q1 FY2022Mar 31, 2022$6.54B-38.5%
Q4 FY2021Dec 31, 2021$8.04B-35.0%
Q3 FY2021Sep 30, 2021$12.92B+13.1%
Q1 FY2021Mar 31, 2021$10.57B+31.9%
Q4 FY2020Dec 31, 2020$10.65B+19.5%
Q3 FY2020Sep 30, 2020$12.36B-43.2%
Q2 FY2020Jun 30, 2020$11.42B-56.6%
Q1 FY2020Mar 31, 2020$8.01B-72.7%
Q4 FY2019Dec 31, 2019$8.91B-70.2%
Q2 FY2019Jun 30, 2019$21.76B-26.0%
Q1 FY2019Mar 31, 2019$26.30B+170.0%
Q4 FY2018Dec 31, 2018$29.30B-29.7%
Q3 FY2018Sep 30, 2018$29.92B+897.4%
Q2 FY2018Jun 30, 2018$29.40B+1018.1%
Q1 FY2018Mar 31, 2018$9.74B+190.1%
Q4 FY2017Dec 31, 2017$41.68B+1186.0%
Q3 FY2017Sep 30, 2017$3.00B-13.9%
Q2 FY2017Jun 30, 2017$2.63B-0.0%
Q1 FY2017Mar 31, 2017$3.36B–
Q4 FY2016Dec 31, 2016$3.24B–
Q3 FY2016Sep 30, 2016$3.49B–
Q2 FY2016Jun 30, 2016$2.63B–

More Amgen figures

See a number that looks wrong?